Literature DB >> 21282720

Macrophages predict treatment outcome in Hodgkin's lymphoma.

Christian Steidl, Pedro Farinha, Randy D Gascoyne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21282720      PMCID： PMC3031684          DOI： 10.3324/haematol.2010.033316

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  30 in total

1.  Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker.

Authors:  R L ten Berge; J J Oudejans; D F Dukers; J W Meijer; G J Ossenkoppele; C J Meijer
Journal:  Leukemia       Date:  2001-03       Impact factor: 11.528

2.  Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood.

Authors:  F E van Leeuwen; W J Klokman; M B Veer; A Hagenbeek; A D Krol; U A Vetter; M Schaapveld; P van Heerde; J M Burgers; R Somers; B M Aleman
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

3.  Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma.

Authors:  Peter Kamper; Knud Bendix; Stephen Hamilton-Dutoit; Bent Honoré; Jens R Nyengaard; Francesco d'Amore
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

4.  Improved prognosis of Epstein-Barr virus associated childhood Hodgkin's lymphoma: study of 47 South African cases.

Authors:  M Engel; M F Essop; P Close; P Hartley; G Pallesen; C Sinclair-Smith
Journal:  J Clin Pathol       Date:  2000-03       Impact factor: 3.411

5.  Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial.

Authors:  M Björkholm; U Axdorph; G Grimfors; K Merk; B Johansson; O Landgren; E Svedmyr; H Mellstedt; G Holm
Journal:  Ann Oncol       Date:  1995-11       Impact factor: 32.976

6.  Macrophage-histiocytes in Hodgkin's disease. The relation of peanut-agglutinin-binding macrophage-histiocytes to clinicopathologic presentation and course of disease.

Authors:  H J Ree; M E Kadin
Journal:  Cancer       Date:  1985-07-15       Impact factor: 6.860

Review 7.  The nature of Reed-Sternberg cells: phenotype, genotype, and other properties.

Authors:  S M Hsu; P L Hsu
Journal:  Crit Rev Oncog       Date:  1994

8.  CD163: a specific marker of macrophages in paraffin-embedded tissue samples.

Authors:  Sean K Lau; Peiguo G Chu; Lawrence M Weiss
Journal:  Am J Clin Pathol       Date:  2004-11       Impact factor: 2.493

9.  Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation.

Authors:  E Salloum; R Doria; W Schubert; D Zelterman; T Holford; K B Roberts; L R Farber; R K Kiehl; J Cardinale; D L Cooper
Journal:  J Clin Oncol       Date:  1996-09       Impact factor: 44.544

10.  Long-term cause-specific mortality of patients treated for Hodgkin's disease.

Authors:  Berthe M P Aleman; Alexandra W van den Belt-Dusebout; Willem J Klokman; Mars B Van't Veer; Harry Bartelink; Flora E van Leeuwen
Journal:  J Clin Oncol       Date:  2003-07-28       Impact factor: 44.544
View more
  18 in total

Review 1.  Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

Authors:  Catherine S Diefenbach; Joseph M Connors; Jonathan W Friedberg; John P Leonard; Brad S Kahl; Richard F Little; Lawrence Baizer; Andrew M Evens; Richard T Hoppe; Kara M Kelly; Daniel O Persky; Anas Younes; Lale Kostakaglu; Nancy L Bartlett
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

Review 2.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

3.  Three-dimensional Telomere Signatures of Hodgkin- and Reed-Sternberg Cells at Diagnosis Identify Patients with Poor Response to Conventional Chemotherapy.

Authors:  Hans Knecht; Narisorn Kongruttanachok; Bassem Sawan; Josée Brossard; Sylvain Prévost; Eric Turcotte; Zelda Lichtensztejn; Daniel Lichtensztejn; Sabine Mai
Journal:  Transl Oncol       Date:  2012-08-01       Impact factor: 4.243

4.  CD68/macrosialin: not just a histochemical marker.

Authors:  Dimitry A Chistiakov; Murry C Killingsworth; Veronika A Myasoedova; Alexander N Orekhov; Yuri V Bobryshev
Journal:  Lab Invest       Date:  2016-11-21       Impact factor: 5.662

Review 5.  The role of the tumor microenvironment in HIV-associated lymphomas.

Authors:  Joseph G Taylor; Konstantinos Liapis; John G Gribben
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

6.  Flow cytometry for assessment of the tumor microenvironment in pediatric Hodgkin lymphoma.

Authors:  Meret Henry; Steven Buck; Süreyya Savaşan
Journal:  Pediatr Blood Cancer       Date:  2018-07-15       Impact factor: 3.167

7.  Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial.

Authors:  King L Tan; David W Scott; Fangxin Hong; Brad S Kahl; Richard I Fisher; Nancy L Bartlett; Ranjana H Advani; Rena Buckstein; Lisa M Rimsza; Joseph M Connors; Christian Steidl; Leo I Gordon; Sandra J Horning; Randy D Gascoyne
Journal:  Blood       Date:  2012-09-04       Impact factor: 22.113

8.  Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma.

Authors:  David W Scott; Fong Chun Chan; Fangxin Hong; Sanja Rogic; King L Tan; Barbara Meissner; Susana Ben-Neriah; Merrill Boyle; Robert Kridel; Adele Telenius; Bruce W Woolcock; Pedro Farinha; Richard I Fisher; Lisa M Rimsza; Nancy L Bartlett; Bruce D Cheson; Lois E Shepherd; Ranjana H Advani; Joseph M Connors; Brad S Kahl; Leo I Gordon; Sandra J Horning; Christian Steidl; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-11-26       Impact factor: 44.544

Review 9.  Clinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor Cells.

Authors:  Calogero Vetro; Alessandra Romano; Flavia Ancora; Francesco Coppolino; Maria V Brundo; Salvatore A Raccuia; Fabrizio Puglisi; Daniele Tibullo; Piera La Cava; Cesarina Giallongo; Nunziatina L Parrinello
Journal:  Front Oncol       Date:  2015-05-21       Impact factor: 6.244

10.  Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients.

Authors:  Rajendra Gharbaran; Andre Goy; Takemi Tanaka; Jongwhan Park; Chris Kim; Nafis Hasan; Swathi Vemulapalli; Sreeja Sarojini; Madalina Tuluc; Kip Nalley; Pritish Bhattacharyya; Andrew Pecora; K Stephen Suh
Journal:  J Hematol Oncol       Date:  2013-08-29       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.